CA2095141A1 - Therapie synergique allianmt des combinaisons d'anticorps antitumoraux et d'agents actifs biologiquement - Google Patents

Therapie synergique allianmt des combinaisons d'anticorps antitumoraux et d'agents actifs biologiquement

Info

Publication number
CA2095141A1
CA2095141A1 CA002095141A CA2095141A CA2095141A1 CA 2095141 A1 CA2095141 A1 CA 2095141A1 CA 002095141 A CA002095141 A CA 002095141A CA 2095141 A CA2095141 A CA 2095141A CA 2095141 A1 CA2095141 A1 CA 2095141A1
Authority
CA
Canada
Prior art keywords
tumor
antibody
cells
antibodies
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002095141A
Other languages
English (en)
Inventor
Ingegerd Hellstrom
Karl E. Hellstrom
George Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2095141A1 publication Critical patent/CA2095141A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002095141A 1990-11-05 1991-10-18 Therapie synergique allianmt des combinaisons d'anticorps antitumoraux et d'agents actifs biologiquement Abandoned CA2095141A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60955790A 1990-11-05 1990-11-05
US609,557 1990-11-05

Publications (1)

Publication Number Publication Date
CA2095141A1 true CA2095141A1 (fr) 1992-05-06

Family

ID=24441285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002095141A Abandoned CA2095141A1 (fr) 1990-11-05 1991-10-18 Therapie synergique allianmt des combinaisons d'anticorps antitumoraux et d'agents actifs biologiquement

Country Status (4)

Country Link
EP (1) EP0556285A4 (fr)
JP (1) JPH06501705A (fr)
CA (1) CA2095141A1 (fr)
WO (1) WO1992007466A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
EP0752248B1 (fr) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à differentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
WO1998009651A1 (fr) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha COMPLEXES D'ANTICORPS ANTI-INTEGRINE α3
CN1689646A (zh) 1998-08-11 2005-11-02 拜奥根Idec公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
DK2055313T3 (en) 1998-11-09 2015-07-27 Biogen Inc Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1918305A1 (fr) 1999-08-11 2008-05-07 Biogen Idec Inc. Nouveaux paramètres cliniques pour déterminer la toxicité hématologique avant une radioimmunothérapie
EP1519959B1 (fr) 2002-02-14 2014-04-02 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
RS58420B1 (sr) 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
KR100864549B1 (ko) 2004-08-04 2008-10-20 어플라이드 몰리큘라 에볼류션, 인코포레이티드 변이체 ｆｃ 영역
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
BRPI0917204A2 (pt) 2008-07-21 2015-12-01 Immunomedics Inc variantes estruturais de anticorpos para melhores características terapêuticas
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same

Also Published As

Publication number Publication date
EP0556285A4 (en) 1993-10-27
EP0556285A1 (fr) 1993-08-25
WO1992007466A1 (fr) 1992-05-14
JPH06501705A (ja) 1994-02-24

Similar Documents

Publication Publication Date Title
CA2095141A1 (fr) Therapie synergique allianmt des combinaisons d'anticorps antitumoraux et d'agents actifs biologiquement
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
US8409573B2 (en) Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP0764030B1 (fr) Composition contenant d'autoanticorps pour la therapie et la prophylaxie antitumorale
US5165922A (en) Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
JP4854912B2 (ja) 癌に対する抗体
Weiner et al. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erb B-2 and CD16
AU782569B2 (en) Therapeutic binding agents against MUC-1 antigen and methods of their use
US20080019990A1 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2013189516A1 (fr) Méthode de traitement d'un cancer positif pour gd2
LV11624B (en) Immuno-stimulatory monoclonal antibodies
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
FI114011B (fi) Suonensisäiseen käyttöön tarkoitetun immunoglobuliinin käyttö farmaseuttisen koostumuksen valmistamiseksi syöpäsairauksien hoitamiseksi
Cheng et al. Recent advances in immunotherapy and monoclonal antibody treatment of cancer
Sunkara Novel approaches to cancer chemotherapy
AU650080B2 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US6440733B1 (en) Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
Matsudaira et al. Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells
JPH115749A (ja) 癌治療医薬品組成物
Reisfeld Monoclonal antibodies in cancer immunotherapy
WO2023095929A1 (fr) Agent pour le traitement de tumeurs malignes
KR20230111071A (ko) 렌바티닙을 포함하는 암의 방사면역치료 보조제
CN103687877B (zh) 人源化免疫调节单克隆抗体的变体
Yeh et al. Radioimmunotherapy of xenografted human bladder cancer using monoclonal antibody against blood group A-related antigen
Baldwin Monoclonal antibodies in the diagnosis, detection and therapy of cancer

Legal Events

Date Code Title Description
FZDE Dead